Cerus Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CERS research report →
Range $4 – $4
Price Chart
About the company
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma.
- CEO
- Vivek K. Jayaraman
- IPO
- 1997
- Employees
- 268
- HQ
- Concord, CA, US
Get TickerSpark's AI analysis on CERS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $373.61M
- P/E
- -47.68
- Fwd P/E
- 61.67
- PEG
- -0.68
- P/S
- 1.65
- P/B
- 4.93
- EV/EBITDA
- -83.80
- Div Yield
- 0.00%
- Gross Margin
- 51.83%
- Op Margin
- -3.87%
- Net Margin
- -3.23%
- ROE
- -10.54%
- ROIC
- -5.61%
Latest fiscal year · YoY change
- Revenue
- $206.13M+14.3%
- Gross Profit
- $112.29M+12.8%
- Op Income
- $-8,681,000
- Net Income
- $-15,627,000+25.3%
- EPS
- $-0.08+25.5%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $3.47
- 52W Low
- $1.59
- 50D MA
- $2.30
- 200D MA
- $2.42
- Beta
- 1.85
- RSI (14)
- 36
- Avg Volume
- 2.12M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cerus delivered 10% product revenue growth, positive REDeS topline results, and another quarter of improving cash generation, while reaffirming full-year guidance and pushing its red-cell and ISC growth stories forward.· November 2, 2026
- Q3 product revenue rose 10% year over year to $57.7 million; 9M product revenue increased 14% to $168.8 million.
- Adjusted EBITDA was positive for the 10th straight quarter at $5.7 million, and cash from operations was $3 million.
- REDeS phase III met its primary efficacy endpoint and showed no statistically significant difference in primary safety endpoints; the company now expects CE Mark clearance in late 2027.
- ISC momentum was strong: U.S. ISC revenue was $5.6 million vs. $3.9 million last year, and 90% of ISC sales shipped in kit form.
- Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, including ISC sales of $23 million to $25 million.
Cerus reported Q3 2026 product revenue of $57.7 million, up 10% year over year, and 9M product revenue of $168.8 million, up 14% from the first nine months of 2025. North American product revenue increased 12%, EMEA product revenue increased 5% as reported, and ISC product revenue was $5.6 million versus $3.9 million a year ago. Gross margin on product sales was 52.4% versus 53.4% in Q3 2025 and 51.4% in Q2 2026. GAAP net loss attributable to Cerus was under $1 million, adjusted EBITDA was $5.7 million versus $5 million last year, and cash, cash equivalents and short-term investments ended at $57.1 million. Management reaffirmed full-year 2026 product revenue guidance of $229 million to $231 million, with ISC sales of $23 million to $25 million.
Vivek Jayaraman framed the quarter as progress on all three priorities: sustainable double-digit growth, innovation, and a stronger financial base. He emphasized the company’s mission to expand safer blood access globally, said the REDeS results are an important step toward red-cell pathogen reduction, and highlighted that ISC and the INT200 rollout are both contributing to growth. His tone was confident and constructive, but he also acknowledged near-term geopolitical and macro headwinds, especially internationally, while stressing that these pressures look transient.
Kevin Green focused on execution versus guidance and the improving economics of the business. He cited 52.4% gross margin, a 10% increase in product revenue, a 5% increase in operating expenses, and $3 million of operating cash generation, with cash and investments at $57.1 million. He also noted that 90% of ISC sales were in kit form, that the kit model should be accretive to consolidated gross margins, and that essentially all ISC sales are expected to be in kit form in 2027. He said the company is refreshing its shelf registration for governance reasons, despite not having used it since 2021.
Analysts focused most heavily on the REDeS path forward, international lumpiness, ISC growth, Germany, and the implications of the Gen 2 device. Management said the next steps for REDeS are full data analysis, submission of the clinical study report to FDA, and publication/podium presentation; they said secondary endpoints are still being analyzed. On international, Jayaraman pointed to Russia/Ukraine-related disruption, deferred French orders, and FX as temporary headwinds, while saying underlying demand and INT200 adoption remain strong. On ISC, he tied the acceleration to the Blood Centers of America agreement, peer-to-peer education, and the transition to the kit model; on Germany, he said the INITIATE study continues to enroll well and policy discussions there could ultimately support adoption.
The bullish case from this call is that Cerus is growing across multiple drivers at once: platelets, ISC, and international INT200 placements. Management sounded increasingly confident in the REDeS data, with a clear regulatory path still ahead and the possibility of real-world European experience helping prepare the market for red cells. The business is also showing operating leverage, with positive adjusted EBITDA for 10 straight quarters, improving margins, and positive cash flow.
The main risks are regulatory timing and external volatility. Management said FDA feedback on the INT200 platelet PMA requires additional data, and CE Mark timing for red cells has slipped to late 2027. International sales are being pressured by geopolitics, deferred orders, and foreign exchange, while the REDeS readout is only topline so secondary endpoints and the full clinical analysis are still pending.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.6%
- Shares Outstanding
- 201.95M
- Float Shares
- 191.08M
of shares held by institutions
192 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 21.58M | ▼ 630.62K |
| Ark Investment Management LLC | 20.51M | ▲ 2.58M |
| Vanguard Group Inc | 11.16M | ▲ 379.13K |
| Vanguard Capital Management LLC | 8.48M | ▼ 81.24K |
| Mackenzie Financial Corp | 6.53M | ▲ 3.52M |
| Baker Bros. Advisors LP | 6.40M | ▼ 3.61M |
| D. E. Shaw & Co., Inc. | 5.49M | ▲ 1.75M |
| State Street Corp | 5.10M | ▲ 343.93K |
| Senvest Management, LLC | 5.04M | ▲ 427.71K |
| Acadian Asset Management LLC | 4.99M | ▲ 714.99K |
| Geode Capital Management, LLC | 4.72M | ▼ 396.64K |
| Amova Asset Management Americas, Inc. | 4.49M | ▲ 360.45K |
Held by 150 ETFs
Biggest fund positions in CERS by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 17, 26 | Jensen Chrystal | sell | 30,000 |
| Jul 16, 26 | Jayaraman Vivek K | sell | 16,666 |
| Jun 30, 26 | Green Kevin Dennis | other | 63,600 |
| Jun 30, 26 | Green Kevin Dennis | sell | 33,676 |
| Jul 1, 26 | Jayaraman Vivek K | other | 554,529 |
| Jun 30, 26 | Jayaraman Vivek K | other | 80,000 |
| Jun 30, 26 | Jayaraman Vivek K | sell | 42,359 |
| Jul 1, 26 | Jayaraman Vivek K | other | 369,686 |
| Jun 30, 26 | Jensen Chrystal | other | 55,000 |
| Jun 30, 26 | Jensen Chrystal | sell | 24,329 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CERS coverage
Recent articles, reports, and earnings notes.
No research on CERS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CERS report →Cerus Corporation to Participate in Upcoming Investor Conferences
businesswire.com · Nov 17
Turning Climate Warnings into Energy Action: Tuya Smart Showcases Its AI Energy Solutions at COP31
gurufocus.com · Nov 16
Cerus Corporation to Participate in the 17th Annual Craig-Hallum Alpha Select Conference
businesswire.com · Nov 11
Cerus Corporation (NASDAQ:CERS) Stock Has Average Target Price of $5.25
defenseworld.net · Nov 11
Cerus: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 3
Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
Cerus Q3 Earnings Call Highlights
marketbeat.com · Nov 2
Cerus' blood-safety system meets main goal in late-stage trial
reuters.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.